Pillar guides
Long-form UK editorial on peptides, GLP-1, and longevity
Pillar guides are 3000-word editorial deep-dives on the questions UK readers ask most. Each is written by Oliver Mackman, sourced with PubMed citations, dated, and reviewed quarterly. No clinical advice. No dosing recommendations. Editorial commentary only.
Body Recomposition: The UK 2026 Editorial Guide to Lean-Mass Preservation on GLP-1 Medication and the Peptide-Research Lane
An editorial UK long-form on body recomposition in 2026: what the GLP-1 lean-mass literature actually shows, the protein-threshold consensus, resistance-training trial framing, and the research-use-only peptide lane that intersects with this conversation.
CJC-1295 (UK pillar guide): DAC and non-DAC variants, preclinical literature, regulatory status
UK editorial pillar on CJC-1295. 30-residue GHRH analogue. DAC (Drug Affinity Complex) and non-DAC variants compared. Preclinical literature, UK retailer landscape, stack context, research-use-only framing.
GHK-Cu (Copper Tripeptide-1): the UK editorial guide
A 3000-word UK editorial pillar on GHK-Cu (Copper Tripeptide-1): molecular structure, age-related plasma decline, preclinical literature, the topical cosmetic vs injectable research lane split, UK regulatory framing, sourcing, stacks and outstanding research questions.
GLP-1 Cost and Supply in the UK: The Full 12-Month Budget Guide
A complete UK breakdown of GLP-1 weight management costs across NHS, private clinic and pharmacy-direct routes. 12-month budget projections, supply considerations and what changes the cost equation.
GLP-1 face: the cosmetic side of rapid weight loss, and what the UK industry is doing about it
An editorial long-form on facial volume loss from GLP-1 medications. What is happening anatomically, what UK dermatology and aesthetic medicine practitioners are observing, and where peptide research-tier topical ingredients sit alongside it.
NHS GLP-1 Rollout Tracker: Which ICBs Are Commissioning Mounjaro and Wegovy in 2026
An editorial map of where the NHS rollout of GLP-1 weight management medication stands across the 42 English Integrated Care Boards, plus the separate pathways in Wales, Scotland and Northern Ireland.
Ipamorelin: UK research-tier pillar on the cleanest ghrelin mimetic
PeptideClear editorial pillar on Ipamorelin. Pentapeptide GHSR agonist. Preclinical literature, comparison with GHRP-2, GHRP-6, Hexarelin, UK retailers and CoA tier. Research use only.
UK Longevity Clinics: The 2026 Editorial Guide for Adults Considering Preventative Health
A 2026 editorial walk-through of the UK longevity clinic landscape. Hooke, Echelon Health, Reliant Healthcare, Human Longevity (UK arm), Bupa Health Clinics and Nuffield Health compared on what they actually do, what they cost, and where the value sits.
BPC-157
BPC-157: UK Editorial Guide to the Gastric Pentadecapeptide
Editorial review of BPC-157: preclinical evidence, UK MHRA status, sourcing notes for UK researchers, and what the literature does not yet show.
NHS access to GLP-1 weight management medications: the patient pathway
An editorial guide to NHS access for GLP-1 weight management medications in 2026. NICE TA1026, Tier-3 referrals, Integrated Care Board commissioning, realistic wait times, and the private alternative. Your GP decides eligibility, not us.
TB-500 (UK): what the Thymosin Beta-4 fragment is, what the preclinical literature shows, and where UK researchers source it
UK editorial pillar on TB-500, the synthetic 17-residue fragment of Thymosin Beta-4. Molecular structure, animal-model evidence (wound, cardiac, neuro, hair), human-trial gaps, MHRA and WADA status, UK retailer landscape, and the Wolverine stack. Research use only, no dosing, no therapeutic claims.